AURO VACCINES LLC
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Subsidiary
- Established
- 2021-11-08
- Employees
- 11
- Market Cap
- -
- Website
- https://aurovaccines.com
Safety and Immunogenicity of a Nipah Virus Vaccine
Phase 1
Completed
- Conditions
- Nipah Virus Infection
- Interventions
- Biological: Normal Saline PlaceboBiological: HeV-sG-V
- First Posted Date
- 2019-12-13
- Last Posted Date
- 2022-11-17
- Lead Sponsor
- Auro Vaccines LLC
- Target Recruit Count
- 192
- Registration Number
- NCT04199169
- Locations
- 🇺🇸
Cincinnati Children's Hospital Medical Center (CCHMC), Cincinnati, Ohio, United States
Trial to Evaluate Safety and Immunogenicity of an Ebola Zaire Vaccine in Healthy Adults
Phase 1
Completed
- Conditions
- Ebola Virus Disease
- Interventions
- Biological: PlaceboBiological: Ebola Vaccine - low doseBiological: Ebola Vaccine - high doseBiological: Ebola Vaccine - mid dose
- First Posted Date
- 2016-03-24
- Last Posted Date
- 2017-04-04
- Lead Sponsor
- Auro Vaccines LLC
- Target Recruit Count
- 38
- Registration Number
- NCT02718469
- Locations
- 🇺🇸
Optimal Research, Melbourne, Florida, United States
© Copyright 2025. All Rights Reserved by MedPath